Docetaxel



- TRADE NAME: Taxotere (Sanofi-Aventis)
- INDICATIONS: Metastatic breast cancer, non-small cell lung cancer; with prednisone in hormone refractory prostate cancer; with cisplatin and fluorouracil for gastric adenocarcinoma and squamous cell carcinoma of the head and neck
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Taxane
- HALF-LIFE: 11–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Aldesleukin, Anthracyclines, Antifungals, Aprepitant, BCG Vaccine, Conivaptan, Cyclosporine, CYP3A4 inhibitors or inducers, Dasatinib, Deferasirox, Denosumab, Echinacea, Erythromycin, Itraconazole, Ketoconazole, Lapatinib, Leflunomide, Natalizumab, P-glycoprotein inhibitors or inducers, Pimecrolimus, Prednisone, Ritonavir, Sipuleucel-T, Sorafenib, St John's Wort, Tacrolimus, Thalidomide, Trastuzumab, Vaccines, Voriconazole
PREGNANCY CATEGORY: D
Contra-indicated in patients with hypersensitivity to docetaxel or polysorbate 80, or with neutrophil counts of <1500 cells/mm3.
TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 12/23/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric